ARGX

Argen X SE ADR

892.87

Oct 30 • 3:59 PM ET -4.98 (-0.55%)

893.30

Aftermarket • 7:30 PM ET +0.43 (0.05%)

Healthcare Biotechnology Netherlands Large NASD

Peers: IMVT REGN ROIV VRDN ALNY AZN JNJ VRTX GMAB AMGN

| Held by: IBB CGGO FBT FENI AVDE BBH DFAI QQQJ TGRT DFIC

Scroll to Statements

Index	-
Market Cap	56.15B
Enterprise Value	51.02B
Income	1.71B
Sales	5.22B
Book/sh	136.01
Cash/sh	82.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1863
IPO	May 18, 2017

P/E	34.03
Forward P/E	24.08
PEG	0.71
P/S	10.75
P/B	6.56
P/C	10.83
P/FCF	48.59
EV/EBITDA	33.19
EV/Sales	9.77
Quick Ratio	4.89
Current Ratio	5.12
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	26.24
EPS next Y	37.08
EPS next Q	8.04
EPS this Y	45.69%
EPS next Y	30.05%
EPS next 5Y	33.82%
EPS past 3/5Y	- -
Sales past 3/5Y	116.43% 151.37%
EPS Y/Y TTM	30.28%
Sales Y/Y TTM	70.57%
EPS Q/Q	104.48%
Sales Q/Q	60.67%
Earnings	Oct 22 BMO
EPS/Sales Surpr.	-2.33% 5.38%

Insider Own	0.19%
Insider Trans	0.00%
Inst Own	45.65%
Inst Trans	-3.82%
ROA	19.92%
ROE	23.62%
ROIC	20.27%
Gross Margin	89.49%
Oper. Margin	28.83%
Profit Margin	32.82%
SMA20	3.32%
SMA50	-5.38%
SMA200	4.46%
Trades

Shs Outstand	62.89M
Shs Float	62.76M
Short Float	2.16%
Short Ratio	3.92
Short Interest	1.35M
52W High	1072.75 -16.77%
52W Low	661.85 34.91%
Volatility	2.50% 2.97%
ATR (14)	28.79
RSI (14)	50.41
Beta	0.47
Rel Volume	1.34
Avg Volume	345.35K
Volume	462,587

Perf Week	2.19%
Perf Month	-4.61%
Perf Quarter	7.47%
Perf Half Y	13.96%
Perf YTD	6.17%
Perf Year	8.84%
Perf 3Y	92.37%
Perf 5Y	195.69%
Perf 10Y	-
Recom	1.29
Target Price	1165.94
Prev Close	897.85
Price	892.87
Change %	-0.55%

Consensus

Strong Buy

Avg. Price Target

$1,165.94

Implied Upside

+30.6%

Analysts12incl. previous ratings

Rating Distribution9 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 26, 2026	Upgrade	UUBS	Neutral → Buy	$1400	+56.8%
Aug 24, 2026	Downgrade	DDeutsche Bank	Buy → Hold
Aug 04, 2026	Resumed	GGuggenheim	Buy	$1185	+32.7%
Mar 10, 2026	Upgrade	DDeutsche Bank	Hold → Buy
Dec 18, 2025	Downgrade	RRobert W. Baird	Outperform → Neutral	$858	-3.9%
Nov 24, 2025	Downgrade	WWolfe Research	Outperform → Peer Perform
Sep 15, 2025	Resumed	TTruist	Buy	$918	+2.8%
Sep 11, 2025	Downgrade	DDeutsche Bank	Buy → Hold
Aug 25, 2025	Initiated	RRBC Capital Mkts	Outperform	$850	-4.8%
Jul 08, 2025	Upgrade	DDeutsche Bank	Hold → Buy
Jul 03, 2025	Resumed	MMorgan Stanley	Overweight	$700	-21.6%
May 13, 2025	Upgrade	RRobert W. Baird	Neutral → Outperform	$680	-23.8%
Mar 17, 2025	Upgrade	BBernstein	Mkt Perform → Outperform
Mar 12, 2025	Upgrade	DDeutsche Bank	Sell → Hold
Jan 17, 2025	Downgrade	DDeutsche Bank	Hold → Sell
Nov 12, 2024	Upgrade	WWolfe Research	Peer Perform → Outperform	$697	-21.9%
Nov 05, 2024	Upgrade	BScotiabank	Sector Perform → Sector Outperform	$715	-19.9%
Nov 01, 2024	Upgrade	WWilliam Blair	Mkt Perform → Outperform
Nov 01, 2024	Downgrade	RRobert W. Baird	Outperform → Neutral	$515 → $650	-27.2%
Oct 10, 2024	Resumed	RRaymond James	Strong Buy	$605	-32.2%

Oct-22-26 03:55PM	Argenx Beats As VYVGART Sales Accelerate, But Forte Costs, A $4 Billion Spending Plan, And Pipeline Pruning Complicate The Story (Earnings Whispers)
09:34AM	TD Cowen Names Top Biotech Stocks for Q4 Amid Market Volatility (Investing.com)
09:15AM	Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans (Investor's Business Daily)
07:03AM	Argenx slips as Q3 operating profit miss offsets Vyvgart sales beat (Investing.com)
01:00AM	argenx Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Oct-19-26 08:00AM	argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026 (GlobeNewswire)
Oct-15-26 12:52PM	Best 3 Non-AI Stocks to Buy Now on the Dip Amid the AI Stock Selloff (Zacks)
01:00AM	argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 (GlobeNewswire)
Oct-14-26 02:54PM	Top biotechnology stock pick from Guggenheim (Investing.com)
Oct-08-26 04:22PM	Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's (Investor's Business Daily) -11.83%
01:33PM	IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug Class (Stocktwits)
11:43AM	Argenx Stock Sinks as Scrapped Vyvgart Trial Erases $3.5 Billion Opportunity (Barrons.com)
11:41AM	argenx shares drop after trial of Vyvgart in Sjögren's disease is halted (Proactive)
11:38AM	Argenx falls as Sjögrens setback offsets celiac drug progress (BioPharma Dive)
10:35AM	argenx Reports Positive Phase 2 Celiac Disease Trial Results, Plans Phase 3 Development of FB102 (InvestorsHub)
09:33AM	Loading…
09:33AM	Argenx Sinks 11% as Sjogrens Trial Halted for Futility: Disappointed by This Outcome (TIKR)
08:19AM	Why Is ARGX Stock Plunging Today? (Stocktwits)
07:45AM	Argenx cans Phase III Vyvgart Sjögrens study on predicted efficacy fail (Clinical Trials Arena)
06:13AM	Argenx Shares Plunge After Autoimmune-Disease Trial Halt (The Wall Street Journal)
04:09AM	Argenx shares plunge 16% after Sjögrens drug trial halted (Investing.com)
01:00AM	argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjogren's Disease (GlobeNewswire)
01:00AM	argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease (GlobeNewswire)
Sep-29-26 08:00AM	argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline (GlobeNewswire)
Sep-23-26 01:45AM	These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. (Barrons.com)
Sep-17-26 04:03PM	argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors (GlobeNewswire)
Sep-01-26 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-26 09:16AM	A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act. (Pharma Voice)
Aug-27-26 08:50AM	argenx Completes Acquisition of Forte Biosciences, Inc. (GlobeNewswire)
Aug-26-26 09:41AM	Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls (The Fly)
Aug-17-26 02:04PM	Argenx Stock Heads for Record After Blockbuster Drug Delivers Another Win (Barrons.com) +16.04%
11:51AM	Loading…
11:51AM	Argenxs stock rises on Phase III autoimmune myositis victory (Clinical Trials Arena)
10:53AM	argenx Phase 3 ALKIVIA Trial Meets Primary Endpoint in Autoimmune Myositis (InvestorsHub)
09:47AM	Argenx's Vyvgart Scored Another Win - Why Shares Bolted Higher (Investor's Business Daily)
06:00AM	Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis (Business Wire)
03:38AM	European Indexes Start Week Mostly Higher, Boosted by Tech, Pharma Stocks (The Wall Street Journal)
01:00AM	argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis (GlobeNewswire)
Aug-07-26 01:06AM	OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... (GuruFocus.com)
Aug-06-26 07:48AM	argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc. (GlobeNewswire)
Aug-03-26 04:01PM	argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 (GlobeNewswire)
Jul-28-26 05:35AM	Argenx signs agreement to buy Forte Biosciences for $2.2bn (Pharmaceutical Technology)
Jul-27-26 09:57PM	Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today? (Stocktwits)
12:23PM	Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B (Proactive)
07:46AM	Argenx to acquire Forte in $2.2B deal for differentiated immune drug (BioPharma Dive)
07:12AM	FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug Maker (Stocktwits)
06:47AM	Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx (InvestorsHub)
06:46AM	Argenx agrees $2.2 billion acquisition of Forte Biosciences to strengthen autoimmune drug pipeline (InvestorsHub)
01:29AM	Argenx to Buy Forte Biosciences for $2.2 Billion (The Wall Street Journal)
01:07AM	argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline (Business Wire)
Jul-23-26 05:02PM	argenx SE (ARGNF) Q2 2026 Earnings Call Highlights: Robust Growth and Strategic Advances (GuruFocus.com) +8.56%
11:30AM	argenx VYVGART Sales Rise 60% as Pipeline Readouts Approach (InvestorsHub)
01:00AM	argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update (GlobeNewswire)
Jul-16-26 01:00AM	argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026 (GlobeNewswire)
Jul-06-26 04:06PM	Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
01:12PM	This Profitable Autoimmune Biotech Trades Near A High And A Buy Point (Investor's Business Daily)
Jul-04-26 08:01AM	Robinhood, Dell Lead 5 Stocks Near Buy Points With AI Tailwinds (Investor's Business Daily)
Jul-01-26 01:14PM	Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth (Investor's Business Daily)
Jun-25-26 11:33AM	Bayer Surges After Winning Its Supreme Court Roundup Challenge (Investor's Business Daily)
Jun-24-26 10:32AM	Can Argenx Retake Its Record High - And A Buy Point - On A New Vyvgart Strategy? (Investor's Business Daily)
Jun-23-26 01:00AM	argenx to Host Autoimmune Myositis R&D Webinar (GlobeNewswire) -5.57%
Jun-03-26 01:00AM	argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026 (GlobeNewswire)
May-28-26 01:00AM	argenx to Host Myositis R&D Webinar on June 23, 2026 (GlobeNewswire)
May-27-26 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
May-20-26 01:20PM	Can a New Arthritis Drug Make Immunovant the Next Biotech Star? (Barrons.com)
11:38AM	2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug (Barrons.com)
May-18-26 08:34AM	The Biology Came First. (Business Wire)
May-11-26 06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive)
May-08-26 05:20PM	argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG (GlobeNewswire)
06:07AM	FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended (BioPharma Dive)
May-07-26 09:03AM	Argenx Obliterates Profit Expectations On 'Solid Print' For Its Immunology Powerhouse (Investor's Business Daily)
08:45AM	Argenx (ARGX) tops earnings expectations despite slight revenue shortfall (InvestorsHub)
01:00AM	argenx Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-06-26 04:30PM	argenx to Present at BofA Securities 2026 Health Care Conference (GlobeNewswire)
04:01PM	argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer (GlobeNewswire)
09:15AM	argenx SE (XBRU:ARGX) Q1 2026: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-30-26 01:00AM	argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 (GlobeNewswire)
Apr-18-26 01:00AM	argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP (GlobeNewswire)
Mar-20-26 04:01PM	argenx announces Annual General Meeting of Shareholders on May 6, 2026 (GlobeNewswire)
Mar-11-26 08:36AM	Deutsche Bank lifts Argenx to Buy as valuation no longer demanding (Investing.com)
Mar-09-26 08:14PM	Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached (Insider Monkey)
Mar-08-26 06:24AM	Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock (Insider Monkey)
Mar-06-26 01:00AM	argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline (GlobeNewswire)
Mar-05-26 11:40AM	KMDA vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Mar-03-26 06:28AM	argenx CEO Karen Massey Reaffirms Vision 2030, Teases VYVGART Catalysts at TD Cowen Conference (MarketBeat)
Mar-02-26 11:24PM	Analyst Report: argenx SE (Morningstar Research)
Feb-26-26 06:51PM	Analyst Report: argenx SE (Morningstar Research) -5.56%
04:09PM	argenx SE (ARGNF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Advances (GuruFocus.com)
10:59AM	argenex Q4 Earnings Call Highlights (MarketBeat)
09:01AM	Argenx Touts Positive Phase 3 Eye Disease Study Results (Benzinga)
01:00AM	argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
12:30AM	argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis (GlobeNewswire)
Feb-25-26 08:17PM	Nurix Therapeutics Stock Sees RS Rating Jump To 82 (Investor's Business Daily)
07:15AM	What To Expect From argenx SE (XBRU:ARGX) Q4 2025 Earnings (GuruFocus.com)
Feb-24-26 01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
01:02PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
07:33AM	Artisan Mid Cap Fund Maintains Its Confidence in Argenx's (ARGX) VYVGART (Insider Monkey)
Feb-23-26 01:00AM	argenx to Present at TD Cowen 46th Annual Healthcare Conference (GlobeNewswire)
Feb-19-26 01:00AM	argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 (GlobeNewswire)
Feb-18-26 11:17AM	Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues (Zacks)
Feb-13-26 10:27AM	Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans (MarketBeat)
Feb-11-26 11:40AM	HRMY vs. ARGX: Which Stock Is the Better Value Option? (Zacks)

Show Previous News

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

M.Sc.Mr. Timothy Van Hauwermeiren EMBA

CEO & Executive DirectorMs. Karen Massey

Chief Financial OfficerMr. Karl Gubitz

Chief Scientific OfficerDr. Peter Ulrichts

General Counsel & Corporate SecretaryMs. Malini Moorthy

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARGX

Argen X SE ADR

Upgrade your Finviz experience